A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.
Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, Cheong JW, Ikezoe T, Naoe T, Akashi K, Morita S, Kosako M, Ikegaya M, Terada W, Kadokura T, Hill J, Miyawaki S, Gill SC, Heinloth A, Hasabou N.
Sawa M, et al. Among authors: kim hj.
Int J Hematol. 2024 Nov 6. doi: 10.1007/s12185-024-03840-x. Online ahead of print.
Int J Hematol. 2024.
PMID: 39503987